Leighann Bailey Selected Research

Irinotecan (Camptosar)

1/2012	Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
6/2011	The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
11/2008	Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
10/2007	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Leighann Bailey Research Topics

Disease

5	Glioblastoma (Glioblastoma Multiforme) 04/2013 - 10/2007
2	Hemorrhage 01/2012 - 06/2011
1	Neoplasms (Cancer) 04/2013
1	Pancreatitis 03/2012
1	Thrombocytopenia (Thrombopenia) 03/2012
1	Wounds and Injuries (Trauma) 01/2012
1	Fatigue 01/2012
1	Pancytopenia 01/2012
1	Glioma (Gliomas) 11/2008
1	Brain Neoplasms (Brain Tumor) 10/2007

Drug/Important Bio-Agent (IBA)

6	Bevacizumab (Avastin)FDA Link 04/2013 - 10/2007
4	Temozolomide (Temodar)FDA LinkGeneric 04/2013 - 06/2011
4	Irinotecan (Camptosar)FDA LinkGeneric 01/2012 - 10/2007
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2008
1	Monoclonal AntibodiesIBA 11/2008

Therapy/Procedure

3	Therapeutics 04/2013 - 01/2012
3	Radiotherapy 03/2012 - 06/2011
1	Drug Tapering 04/2013
1	Salvage Therapy 11/2008